(Q43032670)

12 November 2017

title

HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia (English)

1 reference

12 November 2017

0 references

1 reference

Norah J Shire

1

1 reference

12 November 2017

Paul S Horn

2

1 reference

12 November 2017

Susan D Rouster

3

1 reference

12 November 2017

Sandra Stanford

4

1 reference

12 November 2017

M Elaine Eyster

5

1 reference

12 November 2017

Kenneth E Sherman

6

1 reference

12 November 2017

Multicenter Hemophilia Cohort HCV Study Group

7

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

12 November 2017

1 reference

12 November 2017

volume

44

1 reference

12 November 2017

issue

5

1 reference

12 November 2017

page(s)

1146-1157

1 reference

Relation between HIV-1 and hepatitis C viral load in patients with hemophilia

12 November 2017

cites work

1 reference

Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin

21 January 2018

1 reference

Serum alanine aminotransferase of donors in relation to the risk of non-A,non-B hepatitis in recipients: the transfusion-transmitted viruses study

21 January 2018

1 reference

7 January 2021

Human immunodeficiency and hepatitis virus infections and their associated conditions and treatments among people with haemophilia

1 reference

7 January 2021

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

1 reference

7 January 2021

Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection

1 reference

7 January 2021

Clinical outcomes of HIV-HCV co-infection in a large cohort of hemophiliac patients

1 reference

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

7 January 2021

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

1 reference

7 January 2021

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

1 reference

7 January 2021

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

1 reference

7 January 2021

Poor response to interferon treatment for chronic hepatitis C in human immunodeficiency virus-infected haemophiliacs

1 reference

7 January 2021

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

7 January 2021

Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection

1 reference

7 January 2021

Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients

1 reference

7 January 2021

Comparison of methodologies for quantification of hepatitis C virus (HCV) RNA in patients coinfected with HCV and human immunodeficiency virus

1 reference

7 January 2021

Hepatitis cRNA quasispecies complexity in patients with alcoholic liver disease

1 reference

7 January 2021

Prevalence and changes in hepatitis C virus genotypes among multitransfused persons with hemophilia. The Multicenter Hemophilia Cohort Study

1 reference

7 January 2021

Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels

1 reference

7 January 2021

HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV.

1 reference

7 January 2021

Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection.

1 reference

7 January 2021

HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin

1 reference

7 January 2021

T-lymphocyte populations in hepatitis C and HIV co-infected patients treated with interferon-alfa-2a and ribavirin.

1 reference

7 January 2021

HIV infection and antiretroviral therapy: effect on hepatitis C virus quasispecies variability

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21374

1 reference

release_v3v5uaayazfyxeiyb2txhclz6y

12 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/v3v5uaayazfyxeiyb2txhclz6y

24 November 2022

mapped directly with Wikidata item

1 reference